962 related articles for article (PubMed ID: 16581036)
1. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
2. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
3. A polysomnography study of eszopiclone in elderly patients with insomnia.
McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
[TBL] [Abstract][Full Text] [Related]
4. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
[TBL] [Abstract][Full Text] [Related]
8. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
[TBL] [Abstract][Full Text] [Related]
9. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
10. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
[TBL] [Abstract][Full Text] [Related]
11. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
McCall WV; Blocker JN; D'Agostino R; Kimball J; Boggs N; Lasater B; Haskett R; Krystal A; McDonald WM; Rosenquist PB
J Clin Sleep Med; 2010 Aug; 6(4):322-9. PubMed ID: 20726279
[TBL] [Abstract][Full Text] [Related]
12. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Najib J
Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
[TBL] [Abstract][Full Text] [Related]
13. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial.
Joffe H; Petrillo L; Viguera A; Koukopoulos A; Silver-Heilman K; Farrell A; Yu G; Silver M; Cohen LS
Am J Obstet Gynecol; 2010 Feb; 202(2):171.e1-171.e11. PubMed ID: 20035910
[TBL] [Abstract][Full Text] [Related]
14. The effects of fluoxetine on symptoms of insomnia in depressed patients.
Satterlee WG; Faries D
Psychopharmacol Bull; 1995; 31(2):227-37. PubMed ID: 7491373
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
16. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
[TBL] [Abstract][Full Text] [Related]
17. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Rosenberg R; Caron J; Roth T; Amato D
Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
[TBL] [Abstract][Full Text] [Related]
19. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
20. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Boyle J; Trick L; Johnsen S; Roach J; Rubens R
Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
